Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company pioneering engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. This page provides investors and industry observers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access real-time updates on NK cell therapy advancements, financial results, regulatory milestones, and partnership agreements. Our curated feed ensures you stay informed about Nkarta’s proprietary cell expansion platform, pipeline progress, and innovations in off-the-shelf immunotherapy solutions.
Key content includes updates on clinical trial phases, manufacturing collaborations, scientific presentations, and corporate governance. Bookmark this page to monitor Nkarta’s progress in developing safer, more accessible cell therapies while maintaining compliance with financial disclosure standards.
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in myasthenia gravis patients.
The treatment protocol involves administering NKX019 on Days 0, 3, and 7 following lymphodepletion with cyclophosphamide. The therapy aims to provide a safe, accessible treatment option for autoimmune diseases through B-cell depletion, potentially enabling long-term remissions via immune system reset.
Patient dosing has begun in both Ntrust-1 and the IST for systemic lupus erythematosus, with preliminary data from Ntrust-1 and Ntrust-2 expected in 2025.
Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 7th Annual Evercore HealthCONx Conference. The company will participate in a fireside chat scheduled for December 4, 2024, at 2:10 p.m. ET.
The event will be accessible through a live webcast on Nkarta's website investor section, with a replay available for approximately 90 days following the presentation.
Nkarta (Nasdaq: NKTX), a company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the Stifel 2024 Healthcare Conference. The company will participate in a fireside chat scheduled for November 19, 2024, at 10:55 a.m. ET. The event will be webcast live on Nkarta's website investor section, with a replay available for approximately 90 days afterward.
Nkarta (NKTX) reported Q3 2024 financial results and corporate updates. The company has initiated patient dosing in both Ntrust-1 and investigator-sponsored trials of NKX019 for autoimmune diseases. Cash position stands at $405.3 million, expected to fund operations into late 2027. The company reported a net loss of $28.3 million ($0.39 per share) for Q3. Notably, Nkarta has decided to discontinue NKX019 development in lymphoma to focus on autoimmune diseases. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials is planned for 2025.
Nkarta, a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, at 12:30 p.m. ET, featuring a fireside chat.
Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website (www.nkartatx.com). For those unable to attend live, a replay of the webcast will be archived on the website for approximately 90 days. This conference participation provides an opportunity for Nkarta to showcase its progress and engage with the investment community.
Nkarta Inc. (NKTX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Enrollment in Ntrust-2, a second clinical trial of NKX019 for autoimmune diseases (systemic sclerosis, myositis, vasculitis), expected to start by year-end 2024.
2. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials planned for 2025.
3. Cash balance of $426.7 million as of June 30, 2024, expected to fund operations into late 2027.
4. Investigator-sponsored trial of NKX019 in systemic lupus erythematosus initiated at Columbia University.
5. Encouraging results from NKX019 retreatment in non-Hodgkin lymphoma patients.
6. Q2 2024 net loss of $25.0 million, or $0.34 per share.
7. R&D expenses were $23.1 million, and G&A expenses were $7.6 million for Q2 2024.
Nkarta Inc. (Nasdaq: NKTX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Enrollment in Ntrust-2, a second clinical trial of NKX019 for autoimmune diseases, is expected to start by year-end 2024.
2. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials planned for 2025.
3. Cash balance of $426.7 million as of June 30, 2024, expected to fund operations into late 2027.
4. Q2 2024 net loss of $25.0 million, or $0.34 per share.
5. R&D expenses were $23.1 million, while G&A expenses were $7.6 million for Q2 2024.
6. Nkarta presented follow-up data from its Phase 1 NKX019 trial in NHL, showing promising results in retreated patients.
7. Leadership updates include new President and Chief Medical Officer appointments.
Nkarta, Inc. (Nasdaq: NKTX) has announced the initiation of an investigator-sponsored trial (IST) of NKX019, their allogeneic, CD19-directed CAR NK-cell therapy, for patients with systemic lupus erythematosus (SLE). The trial, led by Dr. Anca D. Askanase at Columbia University Irving Medical Center, will enroll up to 6 SLE patients, regardless of renal involvement. This IST complements Nkarta's ongoing Phase 1 Ntrust-1 trial of NKX019 in lupus nephritis patients.
The single-center, open-label Phase 1 IST will evaluate safety, clinical outcomes, and include translational and biomarker studies. Patients will receive NKX019 on Days 0, 7, and 14 following lymphodepletion with cyclophosphamide. Nkarta believes NKX019's reduced-toxicity regimen could potentially benefit a broader patient population, including those with less advanced disease.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, has announced significant leadership updates. Nadir Mahmood, Ph.D., has been appointed as President, sharing executive responsibilities with CEO Paul J. Hastings. Additionally, David R. Shook, M.D., has been promoted to Chief Medical Officer, Head of Research & Development.
These changes aim to accelerate the development and commercialization of NK cell therapies. Nkarta has recently initiated Ntrust-1, a clinical trial of NKX019 in lupus nephritis, and received FDA clearance for a second IND application for NKX019 in autoimmune diseases. The company expects to announce preliminary data from the Ntrust-1 and Ntrust-2 clinical trials in 2025.
Nkarta has initiated the Ntrust-1 clinical trial for NKX019 in lupus nephritis with the first patient now in screening.
The company has received FDA clearance for a second IND application for NKX019, enabling the launch of Ntrust-2 to treat systemic sclerosis, myositis, and vasculitis.
Both trials aim to assess the safety and efficacy of NKX019, an allogeneic CAR NK-cell therapy designed to target CD19-positive cells in B-cell mediated diseases.
Data from these trials are expected by 2025.
NKX019 leverages fludarabine-free lymphodepletion and offers on-demand dosing capabilities.
The Ntrust-1 trial involves administering NKX019 on Days 0, 7, and 14, while Ntrust-2 will adopt a different dosing schedule.
Each trial will initially enroll up to 12 patients.
FAQ
What is the current stock price of Nkarta (NKTX)?
What is the market cap of Nkarta (NKTX)?
